How is Montgomery County Built for Bio? Get the Answers from These Life Sciences Execs

Published on :

Montgomery County is well known for many transformative firsts in life sciences. First to sequence the human genome; first gene therapy for sickle cell, first cell therapy for COVID-19 — and that’s just the start.* Montgomery County is an epicenter for translating knowledge into life-changing treatment and cures, with gene and cell therapies representing some of the most promising advancements in human health.

Adaptive Phage Therapeutics Appoints Rob Casper as Vice President of Clinical Operations

Published on :

Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced the appointment of Rob Casper as Vice President of Clinical Operations. Mr. Casper will oversee execution of global clinical trials of APT’s phage bank therapy.

Adaptive Phage Therapeutics Extends Series B to $61 million with Addition of The AMR Action Fund

Published on :

Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the AMR Action Fund has joined an existing $41 million Series B round as a co-investor. The round was initiated in May 2021 and led by Deerfield Management Company, with participation from a second institutional investor and Mayo Clinic. Proceeds of the AMR Action Fund’s investment are primarily intended to support APT’s clinical trials to address substantial unmet patient needs in Prosthetic Joint Infection (PJI) and Diabetic Foot Osteomyelitis (DFO).

Adaptive Phage Therapeutics Announces Strategic Agreement with ARLG to Support Phase 1b/2 Cystic Fibrosis Study

Published on :

GAITHERSBURG, MD, November 2, 2021 – Adaptive Phage Therapeutics, Inc. (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that it has entered into an agreement with the Antibacterial Resistance Leadership Group (ARLG) to support a multi-center Phase 1b/2, randomized, double-blind, placebo-controlled trial assessing the safety and microbiological activity of a single dose of bacteriophage therapy in cystic fibrosis subjects colonized with Pseudomonas aeruginosa. 
ARLG consists of more than 100 leading experts, working together to combat the ongoing antibacterial resistance crisis and improve patient care. Created in 2013, ARLG is funded by a grant from the National Institute of Allergy and Infectious Diseases (NIAID) part of the National Institutes of Health (NIH) under Award Number UM1AI104681. It is facilitated by the Duke Clinical Research Institute and works under the leadership of an executive committee, four component centers, and two Principal Investigators: Vance Fowler, MD, of Duke University, and Henry “Chip” Chambers, MD, of University of California, San Francisco. The NIAID is the Sponsor of this study.

Adaptive Phage Therapeutics Awarded Additional $8 Million from U.S. Department of Defense for Clinical Advancement of Phage to Address Unmet Needs in Infectious Diseases

Published on :

Adaptive Phage Therapeutics Awarded Additional $8 Million from U.S. Department of Defense for Clinical Advancement of Phage to Address Unmet Needs in Infectious Diseases
SEPTEMBER 30, 2021
-Additional award brings APT’s total funding from the U.S. Department of Defense to $31.2 million–
–Will support APT’s PhageBankTM clinical stage programs targeting infectious diseases-
GAITHERSBURG, MD, September 30, 2021 – Adaptive Phage Therapeutics, Inc. (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the Department of Defense (DoD) has awarded the company an additional $8 million for the continued development of bacteriophage therapies (PhageBankTM) for the treatment of infectious diseases. The new funding brings the total contract awarded to APT to $31.2 million. 
“We are thrilled to have the ongoing support of the DoD in the advanced development of our PhageBank™ platform to treat drug-resistant infections across multiple indications,” said Greg Merril, CEO and co-founder of Adaptive Phage Therapeutics.  “We are thankful for the opportunity to collaborate with the U.S. military to create potentially lifesaving therapies for our nation’s service members.” 

Adaptive Phage Therapeutics Appoints Michele Wales, Ph.D., J.D., as Chief Legal Officer

Dr. Wales joins APT with extensive experience in litigation and intellectual property law, specifically within the life sciences industry.
Published on :

Adaptive Phage Therapeutics, Inc., a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that it has appointed Michele Wales, Ph.D., J.D., as Chief Legal Officer. Dr. Wales joins APT with extensive experience in litigation and intellectual property law, specifically within the life sciences industry.

Adaptive Phage Therapeutics Expands Board Following Series B Financing Led by Deerfield Management

Published on :

Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced the appointment of Evan Loh, M.D., CEO of Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), Jonathan Leff, Partner at Deerfield Management, and Jana Jensen, Ph.D., Chief Operating Officer at Deerfield Discovery and Development, to the company’s Board of Directors.

Adaptive Phage Therapeutics Announces Collaboration with Oyster Point Pharma to Target Ophthalmic Diseases

Published on :

Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced a newly-formed research collaboration with Oyster Point Pharma, Inc. (Nasdaq: OYST) for developing therapies, using APT’s PhageBank™ technology, potentially targeting multiple ophthalmic diseases.

Gaithersburg’s Adaptive Phage Therapeutics Announces FDA Clearance of IND Application for PhageBank™ in Treatment of Diabetic Foot Osteomyelitis

Published on :

Adaptive Phage Therapeutics Announces FDA Clearance of IND Application for PhageBank™ in Treatment of Diabetic Foot Osteomyelitis GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to advancing therapies [….]